FEXUCLUE
Live / Registered — Registered (as of 01 Aug 2023)
What this means for you
Registered since 01 Aug 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79335933
- Registration number
- 7123404
- Mark type
- Design + words
- Filed
- 19 Jan 2022
- Published for opposition
- 16 May 2023
- Registered
- 01 Aug 2023
- Attorney of record
- Diane J. Mason
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical agents affecting digestive organs; medicines for treating intestinal disorders; Pharmaceutical preparations in the nature of proton-pump inhibitors for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; medicines for the treatment of gastrointestinal diseases; medicines for human purposes for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; ethical medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection
Owner
Prosecution history
- 27 Nov 2023 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 10 Nov 2023 — NEW REPRESENTATIVE AT IB RECEIVED
- 02 Nov 2023 — FINAL DISPOSITION NOTICE SENT TO IB
- 01 Nov 2023 — FINAL DISPOSITION PROCESSED
- 01 Nov 2023 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 01 Aug 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 01 Aug 2023 — REGISTERED-PRINCIPAL REGISTER
- 17 May 2023 — NOTIFICATION PROCESSED BY IB
- 16 May 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 16 May 2023 — PUBLISHED FOR OPPOSITION
- 26 Apr 2023 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 26 Apr 2023 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
- 26 Apr 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 13 Apr 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 20 Mar 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED